FIV vector with Mouse U6 Promoter driving a scrambled miRNA control miSafe cassette followed by a second reporter cassette containing the CMV (Cytomegalovirus) Promoter driving EGFP. VSVG envelope. Please reference: Boudreau, R. L., et al. (2011). "Rational Design of Therapeutic siRNAs: Minimizing Off-targeting Potential to Improve the Safety of RNAi Therapy for Huntington's Disease." Mol Ther 19(12): 2169-2177. MTA required with Novartis Chiron and Salk Institute for first time external customers. Please contact us at email@example.com for information on initiating the agreements.
*These listed prices are per aliquot for non-profit customers only, additional fees may apply.